Related Experiment Video

Updated: May 11, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Inhibition of the mTOR pathway: a possible protective role in coronary artery disease

Giovanni Tarantino1, Domenico Capone

  • 1Department of Clinical Medicine and Surgery, Federico II University Medical School of Naples, Italy. tarantin@unina.it

Annals of Medicine
|May 15, 2013
PubMed

Insights

Understanding nutrient absorption and fuel allocation is key for obesity and type-II diabetes. This study explores the mammalian target of rapamycin (mTOR) pathway

Area of Science:

  • Metabolic pathways
  • Cellular signaling
  • Nutrient metabolism

Background:

  • Obesity and type-II diabetes involve complex cellular responses to over-nutrition, including altered nutrient absorption and fuel allocation.
  • Lipids and carbohydrates significantly regulate gene transcription of metabolic enzymes, insulin, and adipokines via sterol responsive binding protein (SREBP) and mammalian target of rapamycin (mTOR).
  • Excess adipose tissue increases coronary artery disease risk, with rapamycin showing plaque stabilization in animal models.

Purpose of the Study:

  • To investigate the role of the mammalian target of rapamycin (mTOR) pathway in metabolic diseases.
  • To discuss the molecular mechanisms of mTOR inhibitors.
  • To hypothesize a potential protective role of mTOR inhibitors in atherosclerosis.

Main Methods:

  • Review of existing literature on nutrient metabolism, cellular signaling, and atherosclerosis.
  • Analysis of the mTOR pathway and its regulators.
  • Examination of studies on rapamycin's effects on atherosclerotic plaques.

Main Results:

  • Lipids and carbohydrates are key regulators of metabolic gene expression through SREBP and mTOR.
  • Rapamycin administration attenuated inflammation and improved atherosclerotic plaque stability in animal models.
  • Clinical studies present conflicting evidence regarding the role of mTOR inhibitors in atherosclerosis.

Conclusions:

  • The mTOR pathway is central to nutrient sensing and metabolic regulation.
  • mTOR inhibitors show promise for atherosclerosis treatment, but further clinical validation is needed.
  • Understanding mTOR's complex role is crucial for managing metabolic disorders and cardiovascular disease.

More Related Videos

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...